<DOC>
	<DOCNO>NCT03021018</DOCNO>
	<brief_summary>The purpose study assess efficacy intravenous brivaracetam ( BRV ) compare intravenous lorazepam ( LZP ) subject epilepsy undergoing Epilepsy Monitoring Unit ( EMU ) evaluation experience seizure require prompt treatment .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Brivaracetam Treatment Increased Seizure Activity Epilepsy Monitoring Unit Setting</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Subject male female , 18 70 year age , inclusive Subject establish diagnosis epilepsy Subject admit institution 's Epilepsy Monitoring Unit ( EMU ) seizure characterization noninvasive presurgical evaluation admission plan within 21 day Screening Subject previously participate study treat study drug . Rescreen permit Subject participate another study investigational medicinal product ( IMP ) medical device within previous 30 day Epilepsy Monitoring Unit ( EMU ) admission currently participate another study IMP medical device Subject take brivaracetam ( BRV ) Levetiracetam ( LEV ) 21 day prior EMU admission History presence status epilepticus 6 month prior EMU admission Subject medical psychiatric condition opinion Investigator could jeopardize would compromise subject 's ability participate study Subject &gt; 2x upper limit normal ( ULN ) following : alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase , &gt; ULN total bilirubin Subject chronic liver disease Subject hypersensitivity BRV excipients Subject history alcohol drug abuse 6 month prior EMU admission Subject history psychogenic seizure Subject pregnant lactate female Subject history significant Adverse Event ( AE ) due benzodiazepine opinion Investigator Subject respiratory failure ( risk respiratory failure ) , untreated sleep apnea , severe cardiorespiratory disease New York Heart Association Class III IV functional status , require supplemental oxygen Subject acute narrowangle glaucoma myasthenia gravis Subject receive benzodiazepine treatment ( defined average &gt; =4 administration per week ) start less 28 day prior EMU admission Subject know allergic reaction intolerance benzodiazepine benzodiazepine excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Epilepsy Monitoring Unit</keyword>
	<keyword>Increased seizure activity</keyword>
</DOC>